Compare · AZN vs PTIX
AZN vs PTIX
Side-by-side comparison of AstraZeneca PLC (AZN) and Protagenic Therapeutics Inc. (PTIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and PTIX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $245.79B, about 13178.1x PTIX ($18.7M).
- Over the past year, AZN is down 15.9% and PTIX is down 72.8% - AZN leads by 56.9 points.
- AZN has been more active in the news (13 items in the past 4 weeks vs 4 for PTIX).
- AZN has more recent analyst coverage (25 ratings vs 1 for PTIX).
- Company
- AstraZeneca PLC
- Protagenic Therapeutics Inc.
- Price
- $158.44-0.19%
- $0.73-44.06%
- Market cap
- $245.79B
- $18.7M
- 1M return
- -3.67%
- +0.00%
- 1Y return
- -15.85%
- -72.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 13
- 4
- Recent ratings
- 25
- 1
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Protagenic Therapeutics Inc.
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
Latest AZN
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
- SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
- AstraZeneca results: H1 and Q2 2026
Latest PTIX
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $710 worth of shares (2,220 units at $0.32), increasing direct ownership by 7% to 34,199 units (SEC Form 4)
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $151 worth of shares (685 units at $0.22), increasing direct ownership by 2% to 31,979 units (SEC Form 4)
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $1,294 worth of shares (5,000 units at $0.26), increasing direct ownership by 19% to 31,294 units (SEC Form 4)
- EXEC. CHAIR & PRINCIPAL OFF. Armen Garo H bought $4,806 worth of shares (26,291 units at $0.18) (SEC Form 4)
- SEC Form NT 10-K filed by Protagenic Therapeutics Inc.
- Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
- Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
- Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market